{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T16:19:11Z","timestamp":1772468351255,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"DOI":"10.13039\/501100002957","name":"Technische Universit\u00e4t Dresden","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002957","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Hohe Werte von C\u2011reaktivem Protein (CRP) sind beim systemischen Lupus erythematodes in der Regel nicht Zeichen der Krankheitsaktivit\u00e4t, sondern einer schweren bakteriellen Infektion. Warum das so ist, obwohl die Spiegel von Interleukin(IL)-6, dem wichtigsten CRP-Stimulator, beim aktiven SLE hoch sind, ist seit L\u00e4ngerem eine viel diskutierte Frage. Neu publizierte Ergebnisse geben jetzt eine Antwort darauf: In Kombination mit Interferon alpha (IFN-\u03b1) f\u00fchrt IL\u20116 dazu, dass der IL-6-Rezeptor \u201egeshedded\u201c, also enzymatisch von der Zellmembran abgeschnitten wird. Die l\u00f6slichen Rezeptoren im Plasma bilden einen IL-6-Puffer, der IL\u20116 an Effekten auf Leberzellen hindert. Daher wird dort kein CRP produziert. Bei extrem hohen IL-6-Spiegeln im Rahmen von Infektionen (und selten Lupusserositis oder -arthritis) wird die Pufferkapazit\u00e4t \u00fcberschritten, und die Hepatozyten reagieren durch Produktion von CRP.<\/jats:p>","DOI":"10.1007\/s00393-026-01779-4","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T15:29:31Z","timestamp":1769527771000},"page":"163-166","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Warum das C-reaktive Protein beim SLE (meist) nicht hoch ist","Why C-reactive protein is (usually) not high in SLE"],"prefix":"10.1007","volume":"85","author":[{"given":"Erik","family":"Klapproth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martyna","family":"Hempel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolai","family":"Leuchten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Rose-John","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adelheid","family":"Korb-Pap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4471-8375","authenticated-orcid":false,"given":"Martin","family":"Aringer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"1779_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.102374","volume":"110","author":"M Aringer","year":"2020","unstructured":"Aringer\u00a0M (2020) Inflammatory markers in systemic lupus erythematosus. Journal of autoimmunity 110:102374","journal-title":"Journal of autoimmunity"},{"key":"1779_CR2","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1056\/NEJM199902113400607","volume":"340","author":"C Gabay","year":"1999","unstructured":"Gabay\u00a0C, Kushner\u00a0I (1999) Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340:448\u2013454","journal-title":"N Engl J Med"},{"key":"1779_CR3","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3109\/s101650200049","volume":"12","author":"K Ueki","year":"2002","unstructured":"Ueki\u00a0K, Ikeuchi\u00a0H, Ota\u00a0F et\u00a0al (2002) Extremely high levels of C\u2011reactive protein in patients with acute lupus serositis. Mod.Rheumatol 12:267\u2013270","journal-title":"Mod.Rheumatol"},{"key":"1779_CR4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1177\/0961203313512882","volume":"23","author":"EM Ball","year":"2014","unstructured":"Ball\u00a0EM, Gibson\u00a0DS, Bell\u00a0AL et\u00a0al (2014) Plasma IL\u20116 levels correlate with clinical and ultrasound measures of arthritis in patients with systemic lupus erythematosus. Lupus 23:46\u201356","journal-title":"Lupus"},{"key":"1779_CR5","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1177\/0961203318763732","volume":"27","author":"E Littlejohn","year":"2018","unstructured":"Littlejohn\u00a0E, Marder\u00a0W, Lewis\u00a0E et\u00a0al (2018) The ratio of erythrocyte sedimentation rate to C\u2011reactive protein is useful in distinguishing infection from flare in systemic lupus erythematosus patients presenting with fever. Lupus 27:1123\u20131129","journal-title":"Lupus"},{"key":"1779_CR6","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","volume":"112","author":"N Nishimoto","year":"2008","unstructured":"Nishimoto\u00a0N, Terao\u00a0K, Mima\u00a0T et\u00a0al (2008) Mechanisms and pathologic significances in increase in serum interleukin\u20116 (IL-6) and soluble IL\u20116 receptor after administration of an anti-IL\u20116 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112:3959\u20133964","journal-title":"Blood"},{"key":"1779_CR7","doi-asserted-by":"publisher","first-page":"5294","DOI":"10.4049\/jimmunol.160.11.5294","volume":"160","author":"AJ Szalai","year":"1998","unstructured":"Szalai\u00a0AJ, Van Ginkel\u00a0FW, Dalrymple\u00a0SA et\u00a0al (1998) Testosterone and IL\u20116 requirements for human C\u2011reactive protein gene expression in transgenic mice. J\u00a0Immunol 160:5294\u20135299","journal-title":"J Immunol"},{"key":"1779_CR8","first-page":"565","volume":"18","author":"G Grondal","year":"2000","unstructured":"Grondal\u00a0G, Gunnarsson\u00a0I, Ronnelid\u00a0J et\u00a0al (2000) Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp.Rheumatol 18:565\u2013570","journal-title":"Clin Exp.Rheumatol"},{"key":"1779_CR9","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1093\/rheumatology\/35.11.1067","volume":"35","author":"A Studnicka-Benke","year":"1996","unstructured":"Studnicka-Benke\u00a0A, Steiner\u00a0G, Petera\u00a0P et\u00a0al (1996) Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br.J.Rheumatol 35:1067\u20131074","journal-title":"Br.J.Rheumatol"},{"key":"1779_CR10","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/art.27221","volume":"62","author":"GG Illei","year":"2010","unstructured":"Illei\u00a0GG, Shirota\u00a0Y, Yarboro\u00a0CH et\u00a0al (2010) Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 62:542\u2013552","journal-title":"Arthritis Rheum"},{"key":"1779_CR11","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1002\/art.42926","volume":"76","author":"JT Merrill","year":"2024","unstructured":"Merrill\u00a0JT, Tanaka\u00a0Y, D\u2019cruz\u00a0D et\u00a0al (2024) Efficacy and Safety of Upadacitinib or Elsubrutinib Alone or in Combination for Patients With Systemic Lupus Erythematosus: A\u00a0Phase\u00a02 Randomized Controlled Trial. Arthritis Rheumatol 76:1518\u20131529","journal-title":"Arthritis Rheumatol"},{"key":"1779_CR12","doi-asserted-by":"publisher","first-page":"R87","DOI":"10.1186\/ar1032","volume":"6","author":"C Sjowall","year":"2004","unstructured":"Sjowall\u00a0C, Bengtsson\u00a0AA, Sturfelt\u00a0G et\u00a0al (2004) Serum levels of autoantibodies against monomeric C\u2011reactive protein are correlated with disease activity in systemic lupus erythematosus. Arthritis Res Ther 6:R87\u2013R94","journal-title":"Arthritis Res Ther"},{"key":"1779_CR13","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1002\/art.38408","volume":"66","author":"H Enocsson","year":"2014","unstructured":"Enocsson\u00a0H, Sjowall\u00a0C, Kastbom\u00a0A et\u00a0al (2014) Association of serum C\u2011reactive protein levels with lupus disease activity in the absence of measurable interferon-alpha and a C\u2011reactive protein gene variant. Arthritis Rheumatol 66:1568\u20131573","journal-title":"Arthritis Rheumatol"},{"key":"1779_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.622326","volume":"11","author":"H Enocsson","year":"2020","unstructured":"Enocsson\u00a0H, Gullstrand\u00a0B, Eloranta\u00a0ML et\u00a0al (2020) C\u2011Reactive Protein Levels in Systemic Lupus Erythematosus Are Modulated by the Interferon Gene Signature and CRP Gene Polymorphism rs1205. Frontiers in immunology 11:622326","journal-title":"Frontiers in immunology"},{"key":"1779_CR15","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","volume":"382","author":"EF Morand","year":"2020","unstructured":"Morand\u00a0EF, Furie\u00a0R, Tanaka\u00a0Y et\u00a0al (2020) Trial of Anifrolumab in Active Systemic Lupus Erythematosus. N Engl J Med 382:211\u2013221","journal-title":"N Engl J Med"},{"key":"1779_CR16","doi-asserted-by":"crossref","unstructured":"Hempel M, Klapproth E, Krause A et al (2025) Type I interferon limits interleukin\u20116 signaling in SLE through shedding interleukin\u20116 receptors. Rheumatology (Oxford) 64:5793-5802","DOI":"10.1093\/rheumatology\/keaf281"},{"issue":"Suppl 3","key":"1779_CR17","doi-asserted-by":"publisher","first-page":"S233","DOI":"10.1186\/ar565","volume":"4","author":"T Naka","year":"2002","unstructured":"Naka\u00a0T, Nishimoto\u00a0N, Kishimoto\u00a0T (2002) The paradigm of IL-6: from basic science to medicine. Arthritis Res 4(Suppl 3):S233\u2013S242","journal-title":"Arthritis Res"},{"key":"1779_CR18","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/s41577-023-00856-y","volume":"23","author":"S Rose-John","year":"2023","unstructured":"Rose-John\u00a0S, Jenkins\u00a0BJ, Garbers\u00a0C et\u00a0al (2023) Targeting IL\u20116 trans-signalling: past, present and future prospects. Nat Rev Immunol 23:666\u2013681","journal-title":"Nat Rev Immunol"},{"key":"1779_CR19","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1177\/0961203315585815","volume":"24","author":"Z Cai","year":"2015","unstructured":"Cai\u00a0Z, Wong\u00a0CK, Kam\u00a0NW et\u00a0al (2015) Aberrant expression of regulatory cytokine IL-35 in patients with systemic lupus erythematosus. Lupus 24:1257\u20131266","journal-title":"Lupus"},{"key":"1779_CR20","doi-asserted-by":"publisher","first-page":"E411","DOI":"10.1152\/ajpendo.00166.2019","volume":"317","author":"S Aparicio-Siegmund","year":"2019","unstructured":"Aparicio-Siegmund\u00a0S, Garbers\u00a0Y, Flynn\u00a0CM et\u00a0al (2019) The IL-6-neutralizing sIL-6R-sgp130 buffer system is disturbed in patients with type 2 diabetes. Am J Physiol Endocrinol Metab 317:E411\u2013E420","journal-title":"Am J Physiol Endocrinol Metab"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-026-01779-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-026-01779-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-026-01779-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T15:29:34Z","timestamp":1772465374000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-026-01779-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1779"],"URL":"https:\/\/doi.org\/10.1007\/s00393-026-01779-4","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"assertion":[{"value":"6 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.\u00a0Aringer gibt Advisory boards und\/oder Vortr\u00e4ge f\u00fcr AbbVie, AstraZeneca, Chugai, Galapagos, GSK, Lilly, Pfizer und Roche und Sanofi an. N. Leuchten: Advisory boards und Vortr\u00e4ge f\u00fcr Roche. Stefan Rose-John gibt Beratungst\u00e4tigkeit und Vortr\u00e4ge f\u00fcr AbbVie, Chugai, Genentech Roche, Regeneron, Pfizer und Sanofi an, ist Erfinder auf Patenten im Eigentum des CONARIS Research Institutes (Ko-Entwickler des sgp130Fc-Proteins Olamkicept gemeinsam mit Ferring Pharmaceuticals und I-Mab Biopharma), und h\u00e4lt Aktien von CONARIS. E.\u00a0Klapproth, M.\u00a0Hempel und A.\u00a0Korb-Pap geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}